TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 36266539
Drug: Baxdrostat 1.5
Approvals — FDA: no, EMA: no, PMDA: no
Description: Baxdrostat 1.5 mg
Study: 36266539
Drug: Baxdrostat 2.5
Approvals — FDA: no, EMA: no, PMDA: no
Description: Baxdrostat 2.5 mg
Study: 36266539
Drug: Baxdrostat 5.0
Approvals — FDA: no, EMA: no, PMDA: no
Description: Baxdrostat 5.0 mg
Study: 32201109
Drug: Transdermal buprenorphine
Normalized name: buprenorphine Transdermal System
DrugBank: Buprenorphine (DB00921)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Transdermal buprenorphine (TDB) patch 5 mcg applied at the end of surgery
Study: 32201109
Drug: Conventional analgesics
Normalized name: Analgesic Balm GRX
Approvals — FDA: no, EMA: no, PMDA: no
Description: Conventional analgesics (combination of paracetamol and tramadol)
Study: 33749571
Drug: Thiamine 1.5
Normalized name: thiamine 1.5 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Thiamine 1.5 mg/kg
Study: 32149954
Drug: Ingenol Mebutate
Normalized name: Ingenol Mebutate
DrugBank: Ingenol mebutate (DB05013)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Ingenol Mebutate Gel 0.05%
Study: 32149954
Drug: Podophyllin Solution
Normalized name: podophyllin
DrugBank: Podophyllin (DB09094)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Podophyllin Solution 25%
Study: 35114980
Drug: Ward-based intervention
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ward-based intervention plus treatment as usual
Study: 32553436
Drug: Cocktail therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cocktail therapy (20 mL of 0.75% ropivacaine, 5 mg of morphine, 0.3 mg of epinephrine, 2 mg of betamethasone, saline solution to a total of 42 mL)
Study: 32553436
Drug: Cocktail therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cocktail therapy
Study: 32553436
Drug: Control (20
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control (20 mL of 0.75% ropivacaine and saline solution to a total of 42 mL)
Study: 36063807
Drug: Nutritional formula
Approvals — FDA: no, EMA: no, PMDA: no
Description: Nutritional formula (good consumers, intake ≥50% of recommended dose)
Study: 36063807
Drug: Nutritional formula
Approvals — FDA: no, EMA: no, PMDA: no
Description: Nutritional formula (poor consumers, intake <50% of recommended dose)
Study: 34909955
Drug: Group hope
Normalized name: Streptococcus viridans group
Approvals — FDA: no, EMA: no, PMDA: no
Description: Group hope therapy (8 sessions of 90 minutes each using Snyder's method)
Study: 34909955
Drug: Group hope
Normalized name: Streptococcus viridans group
Approvals — FDA: no, EMA: no, PMDA: no
Description: Group hope therapy
Study: 34320552
Drug: Cognitive Behavioral
Normalized name: Mahana Parallel Digital Cognitive Behavioral Therapy Mobile Application for Irritable Bowel Syndrome
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cognitive Behavioral Therapy for Sleep Disturbance and Fatigue (CBT‐SF)
Study: 32475914
Drug: Hypnotic drug
Normalized name: Synotic
DrugBank: Fluocinolone acetonide (DB00591)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Hypnotic drug use (including benzodiazepine receptor agonists)
Study: 32475914
Drug: Benzodiazepine receptor
Normalized name: GABA-benzodiazepine receptor
Approvals — FDA: no, EMA: no, PMDA: no
Description: Benzodiazepine receptor agonists
Study: 34952953
Drug: CPAP treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: CPAP treatment for 1 year
Study: 34647795
Drug: Surfactant (10
Approvals — FDA: no, EMA: no, PMDA: no
Description: Surfactant (10 mg/mL dipalmitoylphosphatidylcholine; DPPC)
Study: 34288546
Drug: i.v. high-dose
Approvals — FDA: no, EMA: no, PMDA: no
Description: i.v. high-dose furosemide plus HSS
Study: 32270926
Drug: Fenebrutinib 150
Normalized name: Fenebrutinib
DrugBank: Fenebrutinib (DB14785)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Fenebrutinib 150 mg once daily
Study: 32479750
Drug: Acetazolamide 62.5
Approvals — FDA: no, EMA: no, PMDA: no
Description: Acetazolamide 62.5 mg twice daily
Study: 32770531
Drug: Ticagrelor loading
Normalized name: Ticagrelor
DrugBank: Ticagrelor (DB08816)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Ticagrelor loading dose (180 mg)
Study: 33632264
Drug: HETROM-2.5 (2.5
Approvals — FDA: no, EMA: no, PMDA: no
Description: HETROM-2.5 (2.5 mg hetrombopag once daily)
Study: 33632264
Drug: HETROM-5 (5
Approvals — FDA: no, EMA: no, PMDA: no
Description: HETROM-5 (5 mg hetrombopag once daily)
Study: 33963089
Drug: Soya milk
Normalized name: MILK
DrugBank: Cow milk (DB10543)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Soya milk preparation offered to intervention group
Study: 34018237
Drug: e-Oral health
Normalized name: vitamin E Oral Capsule
Approvals — FDA: no, EMA: no, PMDA: no
Description: e-Oral health text messages
Study: 32754748
Drug: High-dose SRL
Approvals — FDA: no, EMA: no, PMDA: no
Description: High-dose SRL (lanreotide 120 mg/octreotide long-acting release [LAR] 30 mg) plus weekly pegvisomant (40-160 mg/week)
Study: 32754748
Drug: Low-dose SRL
Normalized name: ethinyl estradiol
DrugBank: Ethinylestradiol (DB00977)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Low-dose SRL (lanreotide 60 mg/octreotide LAR 10 mg) plus weekly pegvisomant
Study: 32754748
Drug: Low-dose SRL
Normalized name: ethinyl estradiol
DrugBank: Ethinylestradiol (DB00977)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Low-dose SRL plus daily pegvisomant (15-60 mg/day)
Study: 32754748
Drug: High-dose SRL
Approvals — FDA: no, EMA: no, PMDA: no
Description: High-dose SRL (lanreotide 120 mg/octreotide LAR 30 mg) plus weekly pegvisomant (40-160 mg/week)
Study: 33417306
Drug: Deep learning
Normalized name: Deep Sea
Approvals — FDA: no, EMA: no, PMDA: no
Description: Deep learning model using molecular descriptors as drug structure information
Study: 35129211
Drug: Patching treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Patching treatment
Study: 33640444
Drug: Dexmedetomidine 0.5
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dexmedetomidine 0.5 mcg/kg
Study: 33640444
Drug: Fentanyl 1.5
Normalized name: fentanyl 1.5 MG/ML
Approvals — FDA: no, EMA: no, PMDA: no
Description: Fentanyl 1.5 mcg/kg
Study: 32681463
Drug: Oral contraceptives
Normalized name: VCF Contraceptive
DrugBank: Nonoxynol-9 (DB06804)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral contraceptives containing Cyproterone Acetate (CPA)
Study: 32681463
Drug: Oral contraceptives
Normalized name: VCF Contraceptive
DrugBank: Nonoxynol-9 (DB06804)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral contraceptives containing Levonorgestrel (LNG)
Study: 32681463
Drug: Oral contraceptives
Normalized name: VCF Contraceptive
DrugBank: Nonoxynol-9 (DB06804)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral contraceptives containing Desogestrel (DSG)
Study: 32681463
Drug: Oral contraceptives
Normalized name: VCF Contraceptive
DrugBank: Nonoxynol-9 (DB06804)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral contraceptives containing Drospirenone (DRSP)
Study: 34039690
Drug: Continuous glucose
Normalized name: sub-q infusion pump w/continuous glucose monitor
Approvals — FDA: no, EMA: no, PMDA: no
Description: Continuous glucose monitoring (CGM) with alarms set at 2.61-10 mmol/L (47-180 mg/dL)
Study: 34039690
Drug: Control group
Normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control group with alarms set at 3.44-7.78 mmol/L (62-140 mg/dL)
Study: 33516483
Drug: Dexamethasone (DEX)
Normalized name: Dexamethasone
DrugBank: Dexamethasone acetate (DB14649)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Dexamethasone (DEX) 1.5 mg/kg of diet
Study: 33516483
Drug: Dexamethasone (DEX)
Normalized name: Dexamethasone
DrugBank: Dexamethasone acetate (DB14649)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Dexamethasone (DEX) 1.5 mg/kg of diet and omega-3 fatty acids supplementation
Study: 35488238
Drug: Sequential interventions
Normalized name: hydroquinone
DrugBank: Hydroquinone (DB09526)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Sequential interventions
Study: 34508740
Drug: Iron infusion
Approvals — FDA: no, EMA: no, PMDA: no
Description: Iron infusion (iron (III)-hydroxide sucrose; 200mg)
Study: 33278048
Drug: Zirconia implant
Normalized name: zirconium
Approvals — FDA: no, EMA: no, PMDA: no
Description: Zirconia implant under experimental mucositis conditions (Zr-m)
Study: 33278048
Drug: Titanium implant
Approvals — FDA: no, EMA: no, PMDA: no
Description: Titanium implant under experimental mucositis conditions (Ti-m)
Study: 33278048
Drug: Zirconia implant
Normalized name: zirconium
Approvals — FDA: no, EMA: no, PMDA: no
Description: Zirconia implant under healthy conditions (Zr-h)
Study: 33278048
Drug: Titanium implant
Approvals — FDA: no, EMA: no, PMDA: no
Description: Titanium implant under healthy conditions (Ti-h)
Study: 35916813
Drug: 5.2 g
Normalized name: Veltassa 25.2 GM Powder for Oral Suspension
Approvals — FDA: no, EMA: no, PMDA: no
Description: 5.2 g PHGG daily for 12 weeks
Study: 36461909
Drug: Pedometer-based walking
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pedometer-based walking program (>7500 steps/day for 5 days/week) plus resistance exercise (elastic band, twice/week)
Study: 33754800
Drug: Intra-articular allogenic
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intra-articular allogenic lyophilized growth factors (L-GFs), two doses at baseline and after 2 months
Study: 33278935
Drug: Pembrolizumab plus
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pembrolizumab plus chemotherapy (200 mg every 3 weeks plus nab-paclitaxel, paclitaxel, or gemcitabine plus carboplatin)
Study: 33660114
Drug: Black seed
Normalized name: BLACK SEED
Approvals — FDA: no, EMA: no, PMDA: no
Description: Black seed raisin (90 g per day)
Study: 32352493
Drug: AAV8.CNGA3 gene
Approvals — FDA: no, EMA: no, PMDA: no
Description: AAV8.CNGA3 gene therapy (1.0 × 10^10, 5.0 × 10^10, or 1.0 × 10^11 total vector genomes)
Study: 32352493
Drug: AAV8.CNGA3 gene
Approvals — FDA: no, EMA: no, PMDA: no
Description: AAV8.CNGA3 gene therapy
Study: 33257457
Drug: Polypharmacy (5-9
Approvals — FDA: no, EMA: no, PMDA: no
Description: Polypharmacy (5-9 medications)
Study: 33257457
Drug: Hyperpolypharmacy (10-14
Approvals — FDA: no, EMA: no, PMDA: no
Description: Hyperpolypharmacy (10-14 medications)
Study: 33257457
Drug: Super hyperpolypharmacy
Normalized name: Super Spot Remover
Approvals — FDA: no, EMA: no, PMDA: no
Description: Super hyperpolypharmacy (≥15 medications)
Study: 33257457
Drug: Control group
Normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control group (<5 medications)
Study: 33397442
Drug: Low-dose everolimus
Normalized name: ethinyl estradiol
DrugBank: Ethinylestradiol (DB00977)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Low-dose everolimus and low-dose tacrolimus after alemtuzumab induction therapy
Study: 33397442
Drug: Standard immunosuppression
Approvals — FDA: no, EMA: no, PMDA: no
Description: Standard immunosuppression protocol after alemtuzumab induction therapy
Study: 32101256
Drug: Lebrikizumab 125
Approvals — FDA: no, EMA: no, PMDA: no
Description: Lebrikizumab 125 mg every 4 weeks
Study: 91032514
Drug: HBV vaccine
Approvals — FDA: no, EMA: no, PMDA: no
Description: HBV vaccine 5 microgram
Study: 91032514
Drug: HBV vaccine
Approvals — FDA: no, EMA: no, PMDA: no
Description: HBV vaccine 2 microgram
Study: 35810756
Drug: Intravenous alteplase
Normalized name: Alteplase
DrugBank: Alteplase (DB00009)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Intravenous alteplase plus thrombectomy
Study: 34708555
Drug: Standardized diuretic
Approvals — FDA: no, EMA: no, PMDA: no
Description: Standardized diuretic protocol (Phase 2) based on HFA algorithm, starting with intravenous administration of two times the oral home dose.
Study: 35148750
Drug: Heallagen® (7
Approvals — FDA: no, EMA: no, PMDA: no
Description: Heallagen® (7 g L-arginine, 7 g L-glutamine, 1.5 g HMB)
Study: 33371044
Drug: DPP4 inhibitor
Normalized name: Fibrinolysis inhibitor
DrugBank: Aprotinin (DB06692)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: DPP4 inhibitor
Study: 35511290
Drug: xenogenic bone
Normalized name: bone meal
Approvals — FDA: no, EMA: no, PMDA: no
Description: xenogenic bone + L‐PRF
Study: 34254530
Drug: Intensified induction
Normalized name: human sputum, Bordetella pertussis infected
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intensified induction with high-doses cytarabine (1500 mg/m2 b.i.d. on days 5-7 of induction)
Study: 36275698
Drug: TMPs‐MTX (intrapleural
Approvals — FDA: no, EMA: no, PMDA: no
Description: TMPs‐MTX (intrapleural infusion of tumor cell-derived microparticles packaging methotrexate)
Study: 35780788
Drug: ChAdOx1 nCoV‐19
Approvals — FDA: no, EMA: no, PMDA: no
Description: ChAdOx1 nCoV‐19 (AZD1222) vaccine
Study: 32008913
Drug: Fatty fish
Approvals — FDA: no, EMA: no, PMDA: no
Description: Fatty fish (∼630 g/week)
Study: 32008913
Drug: Nuts (∼200
Approvals — FDA: no, EMA: no, PMDA: no
Description: Nuts (∼200 g/week)
Study: 34558247
Drug: Moxibustion therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Moxibustion therapy (20 minutes, once every other day for 8 weeks)
Study: 34558247
Drug: Donepezil hydrochloride
Normalized name: Donepezil Hydrochloride
DrugBank: Donepezil (DB00843)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Donepezil hydrochloride tablets (5 mg once a day for 8 weeks)
Study: 33331989
Drug: Dacomitinib with
Normalized name: dacomitinib
DrugBank: Dacomitinib (DB11963)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Dacomitinib with dose reduction(s)
Study: 35438304
Drug: Intravenous (IV)
Normalized name: intravenous (IV) infusion pump
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravenous (IV) delta-9 tetrahydrocannabinol (THC) at 0.015 mg/kg
Study: 35438304
Drug: Intravenous (IV)
Normalized name: intravenous (IV) infusion pump
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravenous (IV) delta-9 tetrahydrocannabinol (THC) at 0.03 mg/kg
Study: 35438304
Drug: Intravenous (IV)
Normalized name: intravenous (IV) infusion pump
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravenous (IV) placebo
Study: 34627009
Drug: Pentoxifylline (800
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pentoxifylline (800 mg daily)
Study: 32533875
Drug: Shared oral
Normalized name: ethanol
DrugBank: Ethanol (DB00898)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Shared oral care intervention
Study: 33899261
Drug: Standard oral
Approvals — FDA: no, EMA: no, PMDA: no
Description: Standard oral care programme (Control)
Study: 34776151
Drug: Positional Release
Normalized name: salicylic acid
DrugBank: Salicylic acid (DB00936)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Positional Release Therapy (PRT)
Study: 34034603
Drug: PFMT treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: PFMT treatment as usual (n = 47)
Study: 34039406
Drug: Individualized, low-cost,
Approvals — FDA: no, EMA: no, PMDA: no
Description: Individualized, low-cost, and accessible pulmonary rehabilitation program with weekly physiotherapist supervision
Study: 34039406
Drug: Individualized, low-cost,
Approvals — FDA: no, EMA: no, PMDA: no
Description: Individualized, low-cost, and accessible pulmonary rehabilitation program without weekly physiotherapist supervision
Study: 32386593
Drug: Secukinumab (300
Approvals — FDA: no, EMA: no, PMDA: no
Description: Secukinumab (300 mg subcutaneously at baseline, weeks 1, 2, 3, and 4, then every 4 weeks until week 48)
Study: 32386593
Drug: Adalimumab (40
Approvals — FDA: no, EMA: no, PMDA: no
Description: Adalimumab (40 mg every 2 weeks from baseline until week 50)
Study: 34896242
Drug: PRP injection
Normalized name: Haemophilus influenzae type b, capsular polysaccharide inactivated tetanus toxoid conjugate vaccine
DrugBank: Platelet Rich Plasma (DB19295)
Approvals — FDA: no, EMA: no, PMDA: no
Description: PRP injection in the healing edge and the floor of the targeted DFU (Group A)
Study: 34896242
Drug: Usual standard
Approvals — FDA: no, EMA: no, PMDA: no
Description: Usual standard care with moist dressing with or without collagenase ointment (Group B)
Study: 35183373
Drug: Intravenous golimumab
Normalized name: Golimumab
DrugBank: Golimumab (DB06674)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Intravenous golimumab 2 mg/kg every 6 weeks (Q6W)
Study: 35183373
Drug: Intravenous golimumab
Normalized name: Golimumab
DrugBank: Golimumab (DB06674)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Intravenous golimumab 2 mg/kg every 8 weeks (Q8W)
Study: 34008842
Drug: 900 μg
Approvals — FDA: no, EMA: no, PMDA: no
Description: 900 μg vitamin D3
Study: 34008842
Drug: 900 μg
Approvals — FDA: no, EMA: no, PMDA: no
Description: 900 μg 25(OH)D3
Study: 39282902
Drug: Pembrolizumab (200
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pembrolizumab (200 mg every 3 weeks for 1 year)
Study: 33376581
Drug: Specific meal
Normalized name: bone meal
Approvals — FDA: no, EMA: no, PMDA: no
Description: Specific meal replacement foods given normal adult doses
Study: 32900508
Drug: Intrathecal morphine
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intrathecal morphine 100 μg
Study: 34686365
Drug: ABCD 3
Approvals — FDA: no, EMA: no, PMDA: no
Description: ABCD 3 mg/kg
Study: 34686365
Drug: ABCD 4
Approvals — FDA: no, EMA: no, PMDA: no
Description: ABCD 4 mg/kg
Study: 32757311
Drug: Immediate implant
Normalized name: IR-3535
Approvals — FDA: no, EMA: no, PMDA: no
Description: Immediate implant placement with immediate temporization
Study: 32162420
Drug: Buprenorphine alone
Approvals — FDA: no, EMA: no, PMDA: no
Description: Buprenorphine alone (2 mg)
Study: 35895484
Drug: Fractional flow
Normalized name: LIVER FRACTION
Approvals — FDA: no, EMA: no, PMDA: no
Description: Fractional flow reserve-guided percutaneous coronary intervention with new-generation drug-eluting stents
Study: 34169482
Drug: Oropharyngeal exercise
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oropharyngeal exercise (OPE) in addition to CPAP therapy
Study: 34860575
Drug: Multitiered system
Approvals — FDA: no, EMA: no, PMDA: no
Description: Multitiered system of language support (MTSLS) using Story Champs for 14 weeks, with Tier 1 instruction for 15-20 min a day for 4 weeks followed by Tier 2 intervention for 20 min twice a week for students who did not make adequate progress.
Study: 33417506
Drug: eRAPID (weekly
Approvals — FDA: no, EMA: no, PMDA: no
Description: eRAPID (weekly online symptom reporting for 18 weeks)
Study: 36493386
Drug: 10 mg
Normalized name: biotin 10 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 10 mg THC + 0 mg CBD
Study: 36493386
Drug: 10 mg
Normalized name: biotin 10 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 10 mg THC + 10 mg CBD
Study: 36493386
Drug: 10 mg
Normalized name: biotin 10 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 10 mg THC + 20 mg CBD
Study: 36493386
Drug: 10 mg
Normalized name: biotin 10 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 10 mg THC + 30 mg CBD
Study: 36493386
Drug: Control (0
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control (0 mg THC and CBD)
Study: 32289634
Drug: Vitamin D3
Normalized name: Vitamin D3
DrugBank: Cholecalciferol (DB00169)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Vitamin D3 supplementation (200,000 IU for the first 2 months, then 100,000 IU monthly for 18 months)
Study: 35426283
Drug: Low-dose TXA
Normalized name: ethinyl estradiol
DrugBank: Ethinylestradiol (DB00977)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Low-dose TXA (20 mg/kg)
Study: 35426283
Drug: High-dose TXA
Approvals — FDA: no, EMA: no, PMDA: no
Description: High-dose TXA (50 mg/kg)
Study: 35189082
Drug: Dolutegravir dispersible
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dolutegravir dispersible tablets (5 mg, 10 mg, 15 mg, 20 mg based on weight bands)
Study: 35189082
Drug: Dolutegravir 25
Normalized name: dolutegravir 25 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dolutegravir 25 mg film-coated tablets
Study: 33503531
Drug: Intradermal sterile
Normalized name: Steril-Eyes
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intradermal sterile water injection (ISWI) combined with systemic intravenous dexketoprofen therapy
Study: 33503531
Drug: Systemic intravenous
Normalized name: Vaginal System
Approvals — FDA: no, EMA: no, PMDA: no
Description: Systemic intravenous dexketoprofen therapy alone
Study: 32685542
Drug: Conbercept treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Conbercept treatment (initial intravitreal injection followed by PRN strategy)
Study: 32685542
Drug: Conbercept treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Conbercept treatment
Study: 35393631
Drug: dupilumab ±
Approvals — FDA: no, EMA: no, PMDA: no
Description: dupilumab ± topical corticosteroids
Study: 32663479
Drug: Proprioceptive training
Approvals — FDA: no, EMA: no, PMDA: no
Description: Proprioceptive training program (twice weekly for 12 weeks, 55 minutes per session)
Study: 32663479
Drug: Physical therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Physical therapy intervention program (45 minutes group + 100 minutes individual per week for 12 weeks)
Study: 34257959
Drug: N-acetylcysteine (NAC)
DrugBank: Acetylcysteine (DB06151)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: N-acetylcysteine (NAC) at 1200 mg every 12 hours for 48 hours
Study: 35605807
Drug: Steroid use
Normalized name: Antiinflammatory preparations, non-steroids for topical use
Approvals — FDA: no, EMA: no, PMDA: no
Description: Steroid use
Study: 35982485
Drug: ImpACT +
Normalized name: benzalkonium
DrugBank: Benzalkonium (DB11105)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: ImpACT + intervention (six once-a-week coping intervention sessions and six monthly maintenance sessions)
Study: 35982485
Drug: Control condition
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control condition (three weekly sessions of adapted problem-solving therapy)
Study: 36072875
Drug: Hybutimibe plus
Approvals — FDA: no, EMA: no, PMDA: no
Description: Hybutimibe plus atorvastatin
Study: 34002642
Drug: Total joint
Normalized name: Colgate Total Mouthwash
Approvals — FDA: no, EMA: no, PMDA: no
Description: Total joint arthroplasty using a Touch® implant
Study: 34232582
Drug: Lisdexamfetamine (LDX)
DrugBank: Lisdexamfetamine (DB01255)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Lisdexamfetamine (LDX) 30-70 mg/d (mean 59.1 ± 14.8 mg/d)
Study: 33354956
Drug: Qianlie Beixi
Approvals — FDA: no, EMA: no, PMDA: no
Description: Qianlie Beixi Capsules combined with Magnetic Resonance Electromagnetic Therapy (MREM)
Study: 33354956
Drug: Qianlie Beixi
Approvals — FDA: no, EMA: no, PMDA: no
Description: Qianlie Beixi Capsules (QBC)
Study: 34791789
Drug: Topical cyclosporine
Normalized name: Cyclosporine
DrugBank: Cyclosporine (DB00091)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Topical cyclosporine cream delivered by fractional CO2 laser
Study: 34791789
Drug: Topical clobetasol
Normalized name: clobetasol Topical Foam
Approvals — FDA: no, EMA: no, PMDA: no
Description: Topical clobetasol cream
Study: 36106832
Drug: Oral Contraceptive
Normalized name: VCF Contraceptive
DrugBank: Nonoxynol-9 (DB06804)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral Contraceptive (OC) users
Study: 36644237
Drug: Efruxifermin 50
Normalized name: Efruxifermin
DrugBank: Efruxifermin (DB19012)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Efruxifermin 50 mg once-weekly for 16 weeks
Study: 36129617
Drug: Combination of
Normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination of OTCCST and transitional care (TC)